electroCore to Announce Third Quarter September 30, 2025 Financial Results on Wednesday, November 5, 2025
electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
gammaCore® Non-Invasive Vagus Nerve Stimulation (nVNS) as an Adjunctive Treatment Associated with Improvements in Persistent Post-Concussion Symptoms
electroCore Announces Reimbursement Approval for gammaCore™ by RIZIV/INAMI in Belgium
The science of nVNS
nVNS therapy stimulates the vagus nerve, which has been proven to help people suffering from a variety of disorders.
Pioneers of technology. Innovators of medicine.
We are pioneering the use of nVNS to deliver bioelectronic medicine for patient benefit.
Our Products. Our Passion.
Find innovative health and wellness solutions with electroCore's products, all utilizing our proprietary vagus nerve stimulation technology.
electroCore is committed to the safety and care of our patients, providers, and employees during the COVID-19 pandemic. We have implemented several operational enhancements, research initiatives, and virtual capabilities to ensure patients who depend on us have uninterrupted access to gammaCoreTM (non-invasive vagus nerve stimulator). To learn more about our efforts please call (888) 903-CORE.
